2019 SABCS Public Thursday

Peter Schmid, MD, PhD discusses Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancerwith Lymph Node Involvement during the Thursday morning Press Conference

San Antonio, TX - SABCS 2019 San Antonio Breast Cancer Symposium - Peter Schmid, MD, PhD discusses Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancerwith Lymph Node Involvement during the Thursday morning Press Conference here today, Thursday December 12, 2019. during the San Antonio Breast Cancer Symposium being held at the Henry B. Gonzalez Convention Center in San Antonio, TX. This year is the 42nd Anniversary of the meeting where over 7,500 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Photo by © MedMeetingImages/Todd Buchanan 2019 Technical Questions: todd@medmeetingimages.com